联环药业公告，第三季度营收为7.97亿元，同比增长53.81%；净利润为496.62万元，同比下降83.34%。 前三季度营收为20.82亿元，同比增长26.63%；净利润为-3506.21万元，同比下降137.82%。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.19% on October 23, with Shuyou leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22%, closing at 13025.45 [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - ST Suwu (code: 600200) with a closing price of 1.01, up 5.21% [1] - Lianhuan Pharmaceutical (code: 600513) closed at 21.13, up 4.14% with a trading volume of 344,100 shares and a turnover of 731 million [1] - ST Nuotai (code: 688076) closed at 38.72, up 4.09% with a trading volume of 67,000 shares and a turnover of 258 million [1] - Conversely, significant decliners included: - Buzou Shen (code: 300204) with a closing price of 35.53, down 7.52% [2] - Haichen Pharmaceutical (code: 300584) closed at 51.72, down 7.25% with a trading volume of 83,600 shares and a turnover of 434 million [2] - Xiangrikui (code: 300111) closed at 8.06, down 6.06% with a trading volume of 2,061,600 shares and a turnover of 1.675 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.547 billion from major funds, while retail investors contributed a net inflow of 2.56 billion [2][3] - Key stocks with significant capital flow included: - Lianhuan Pharmaceutical had a net inflow of 65.45 million from major funds, but a net outflow of 55.76 million from retail investors [3] - Kangzhi Pharmaceutical (code: 300086) saw a net inflow of 27.84 million from major funds, with a minor net outflow from retail investors [3] - Huana Pharmaceutical (code: 688799) had a net inflow of 26.15 million from major funds, but also faced outflows from retail investors [3]

Core Points - The company announced the convening of the 16th temporary meeting of the 9th Board of Directors on October 17, 2025 [2] - The meeting will review the proposal regarding the adjustment of members in various specialized committees [2]

证券代码：600513 证券简称：联环药业 公告编号：2025-081 江苏联环药业股份有限公司 关于调整公司各专门委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于 2025 年 10 月 17 日召 开第九届董事会第十六次临时会议，审议通过了《关于调整公司各专门委员会委 员的议案》，现将相关情况公告如下： 鉴于胡一桥女士辞去公司独立董事、董事会提名委员会召集人及委员、董事 会薪酬与考核委员会委员、董事会战略与可持续发展委员会委员职务。根据《中 华人民共和国公司法》《公司章程》等有关规定，为优化公司治理结构，保障董 事会各专门委员会高效、规范运作，更好地发挥其在公司治理中的专业作用，公 司对董事会各专门委员会进行相应调整。调整后的各专门委员会任期自本次董事 会审议通过之日起至第九届董事会任期届满之日止。具体调整情况如下： 1、战略与可持续发展委员会 调整前：钱振华（召集人）、夏春来、方 芳、胡一桥 调整后：钱振华（召集人）、夏春来、方 芳、牛 犇 2、提名委员会 ...

Core Viewpoint - The A-share market continues to show strength in innovative drug concept stocks, with significant gains observed across multiple companies on October 16 [1] Group 1: Stock Performance - Guizhou BaiLing and Luoxin Pharmaceutical reached the daily limit up [1] - Yifang Bio increased by over 7% [1] - Laime Pharmaceutical, Guangsheng Tang, Anglikang, and Shutaishen all rose by over 6% [1] - Dize Pharmaceutical and Lianhuan Pharmaceutical saw increases of over 5% [1]

Core Viewpoint - Lianhuan Pharmaceutical is actively engaging with institutional investors and focusing on optimizing its product structure through innovative research and development, aiming to enhance overall profitability and reduce reliance on single business segments [1][2]. Group 1: Business Overview - Lianhuan Pharmaceutical's main business includes pharmaceutical manufacturing and distribution, with key products in urology, antihistamines, cardiovascular drugs, steroids, and antibiotics [1]. - The company has established long-term partnerships with production enterprises and traders across North America, South America, Eastern Europe, and Southeast Asia [1]. - In the pharmaceutical distribution sector, subsidiaries maintain stable relationships with numerous well-known pharmaceutical companies and various healthcare institutions [1]. Group 2: Financial Performance and Projections - For the fiscal year 2024, Lianhuan Pharmaceutical projects a revenue of 2.16 billion yuan, with the innovative drug Aipulete tablets expected to sell 119 million tablets [1]. - The company plans to invest 277 million yuan in research and development for 2024, with 145 million yuan allocated for the first half of 2025, focusing on high-value innovative drugs [2]. Group 3: Research and Development - The LH-1801 (SGLT-2 inhibitor) has completed participant enrollment for its clinical trial, with results expected in Q1 2026, marking it as the first domestic product to conduct head-to-head research against the positive control drug Dapagliflozin [2][3]. - The company is advancing several projects, including LH-1802 for acute myeloid leukemia, which is in phase I, and other projects like LH-1901 and LH-2103 are progressing as planned [2]. Group 4: Market Position and Strategy - Lianhuan Pharmaceutical's current product portfolio has limited exposure to national centralized procurement, with only one product, Ebastine tablets, included in the procurement list, minimizing the impact of such policies on the company [3]. - The acquisition of a 51% stake in Longyi Pharmaceutical is based on fair market valuation and includes performance-based clauses, enhancing the company's market presence in the southwest region of China [4]. - The strategic acquisition aims to strengthen the company's channel control in the southwest market, creating a dual-core driving pattern with its headquarters in the Yangtze River Delta [4].

证券代码：600513 证券简称：联环药业 公告编号：2025-080 江苏联环药业股份有限公司 投资者关系活动记录表 投资者关系活动类 别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 光大证券、天风证券、华源证券、广发基金、南华基金、 中金财富、俊远投资、海能投资、华安资管、雪石资产、 如码创投、达浩投资、投关易 时间 2025 年 10 月 14 日 地点 上海 上市公司接待人员 姓名 董事兼总经理：牛犇先生 董事会办公室主任兼证券事务代表：葛楷先生 投资者关系活动主 要内容介绍 1、问：公司当前收入结构如何？仿制药是否已退 出？未来产品策略是什么？ 答：公司 2024 年度实现营业收入 21.60 亿元，其中 医药制造板块，创新药爱普列特片销售 1.19 亿片。公司 正通过"仿创结合"路径主动优化产品结构，通过研发 创新实现管线的换挡升级，并持续加大呼吸系统、肿瘤、 内分泌等新治疗领域的研发投入，以降低对单一板块的 依赖，增强整体盈利韧性。 2、问：公司研发投入增长迅速，资金主要投向哪些 项目？重点创新药进展 ...

每经头条（nbdtoutiao）——出租白银的爆赚机会：年化利率飙升到35%，全球白银正空运往英国套 利，背后是一场史诗级逼空 每经AI快讯，联环药业发布公告称，2025年10月14日，联环药业接受光大证券等投资者调研，公司董 事兼总经理牛犇等人参与接待，并回答了投资者提出的问题。 （记者 曾健辉） ...

Market Overview - The chemical pharmaceutical sector increased by 2.94% on October 15, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Notable stock performances in the chemical pharmaceutical sector include: - Sunflower (300111) closed at 8.11, up 19.97% with a trading volume of 3.1035 million shares [1] - Guangshantang (300436) closed at 120.00, up 17.41% with a trading volume of 298,500 shares [1] - Shutaishen (300204) closed at 36.26, up 12.50% with a trading volume of 597,600 shares [1] - Anglikang (002940) closed at 41.20, up 10.01% with a trading volume of 129,600 shares [1] - Lianhuan Pharmaceutical (600513) closed at 20.90, up 10.00% with a trading volume of 309,500 shares [1] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 2.451 billion yuan from institutional investors, while retail investors experienced a net outflow of 948 million yuan [2][3] - The capital flow for key stocks includes: - Sunflower (300111) had a net inflow of 4.41 billion yuan from institutional investors [3] - Guangshantang (300436) had a net inflow of 2.82 billion yuan from institutional investors [3] - Lianhuan Pharmaceutical (600513) had a net inflow of 1.33 billion yuan from institutional investors [3]

Core Insights - The A-share market has seen a significant rally in innovative drug concept stocks, with notable increases in share prices for several companies [1] Group 1: Stock Performance - Guangxi Shengtang (广生堂) experienced a rise of approximately 18% [2] - Shutaishen (舒泰神) increased by over 12% [2] - Jimin Health (济民健康) and Anglikang (昂利康) both hit the 10% daily limit up [2] - Huahai Pharmaceutical (华海药业) rose by over 9% [2] - Frontier Biologics (前沿生物) increased by over 8% [2] - Hanyu Pharmaceutical (翰宇药业) saw a rise of over 7% [2] - Saily Medical (塞力医疗) and Jiuzhou Pharmaceutical (九洲药业) both increased by over 6% [2] Group 2: Market Capitalization and Year-to-Date Performance - Guangxi Shengtang has a market capitalization of 19.2 billion with a year-to-date increase of 269.02% [2] - Shutaishen has a market capitalization of 17.3 billion with a year-to-date increase of 389.07% [2] - Jimin Health has a market capitalization of 5.76 billion with a year-to-date increase of 61.56% [2] - Anglikang has a market capitalization of 8.31 billion with a year-to-date increase of 213.50% [2] - Huahai Pharmaceutical has a market capitalization of 31.4 billion with a year-to-date increase of 18.92% [2] - Frontier Biologics has a market capitalization of 5.544 billion with a year-to-date increase of 51.64% [2] - Hanyu Pharmaceutical has a market capitalization of 19.2 billion with a year-to-date increase of 68.35% [2] - Saily Medical has a market capitalization of 5.628 billion with a year-to-date increase of 270.91% [2] - Jiuzhou Pharmaceutical has a market capitalization of 18.5 billion with a year-to-date increase of 56.50% [2]